These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22300426)

  • 21. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders.
    Dharnidharka VR; Ruzinova MB; Chen CC; Parameswaran P; O'Gorman H; Goss CW; Gu H; Storch GA; Wylie K
    Cancer Med; 2019 Mar; 8(3):1013-1023. PubMed ID: 30697958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum free light chains in solid organ transplant recipients.
    Kwapisz D
    Clin Transplant; 2021 Jun; 35(6):e14286. PubMed ID: 33715217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals.
    Shiels MS; Landgren O; Costello R; Zingone A; Goedert JJ; Engels EA
    Clin Infect Dis; 2012 Nov; 55(10):e103-8. PubMed ID: 22893577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically.
    Pitman SD; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Berdeja JG; Weiss LM; Wang J
    Am J Surg Pathol; 2006 Apr; 30(4):470-6. PubMed ID: 16625093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.
    Leblond V; Sutton L; Dorent R; Davi F; Bitker MO; Gabarre J; Charlotte F; Ghoussoub JJ; Fourcade C; Fischer A
    J Clin Oncol; 1995 Apr; 13(4):961-8. PubMed ID: 7707124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder.
    Zaffiri L; Frankel C; Bush EJ; Neely ML; Pavlisko EN; Mokrova IL; Luftig MA; Palmer SM
    J Med Virol; 2021 Aug; 93(8):5040-5047. PubMed ID: 33704812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
    Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease.
    Kenagy DN; Schlesinger Y; Weck K; Ritter JH; Gaudreault-Keener MM; Storch GA
    Transplantation; 1995 Sep; 60(6):547-54. PubMed ID: 7570949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.
    Maurer MJ; Cerhan JR; Katzmann JA; Link BK; Allmer C; Zent CS; Call TG; Rabe KG; Hanson CA; Kay NE; Slager SL; Witzig TE; Shanafelt TD
    Blood; 2011 Sep; 118(10):2821-6. PubMed ID: 21765023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
    Kinch A; Sundström C; Tufveson G; Glimelius I
    Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease.
    Montone KT; Hodinka RL; Salhany KE; Lavi E; Rostami A; Tomaszewski JE
    Mod Pathol; 1996 Jun; 9(6):621-30. PubMed ID: 8782198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients.
    Engels EA; Jennings LW; Everly MJ; Landgren O; Murata K; Yanik EL; Pfeiffer RM; Onaca N; Klintmalm GB
    Transplant Direct; 2018 Jun; 4(6):e353. PubMed ID: 30123826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis.
    Capello D; Berra E; Cerri M; Gaidano G
    Minerva Med; 2004 Feb; 95(1):53-64. PubMed ID: 15041926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.
    Jamalidoust M; Geramizadeh B; Pouladfar G; Namayandeh M; Asaie S; Aliabadi N; Nikeghbalian S; Ziyaeyan M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.
    Pardanani A; Lasho TL; Finke CM; Rajkumar SV; Singh PP; Ketterling RP; Hanson CA; Katzmann JA; Tefferi A
    J Clin Oncol; 2012 Apr; 30(10):1087-94. PubMed ID: 22331938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.